During Monday’s trading session, shares of a company engaged in manufacturing Active Pharmaceutical Ingredients (APIs) hit a 10 percent upper circuit, after reporting Q4 FY25 financial results with a rise in net profit by around 49 percent QoQ and 46 percent YoY.
With a market capitalisation of Rs. 137.4 crores, the shares of Smruthi Organics Limited closed in the green at Rs. 120 on BSE, up by nearly 6.2 percent, as against its previous closing price of Rs. 113.05. The stock has delivered negative returns of around 30 percent in one year, but has gained over 11 percent year-to-date.
What’s the News
According to the latest regulatory filings on the BSE, Smruthi Organics Limited announced the financial results for Q4 FY25 on Monday during market hours. For Q4 FY25, Smruthi Organics reported a revenue from operations of Rs. 38 crores, reflecting a growth of around 22 percent QoQ from Rs. 31.2 crores in Q3 FY25, but a marginal year-on-year fall of around 4 percent from Rs. 39.6 crores in Q4 FY24.
The net profit increased to Rs. 2.2 crores in Q4 FY25, marking a nearly 49 percent QoQ rise from Rs. 1.48 crores reported in the previous quarter, and around 46 percent YoY rise compared to Rs. 1.51 crores in Q4 FY24.
Additionally, EBITDA grew to Rs. 4.7 crores in Q4 FY25, representing a 12 percent rise from Rs. 4.2 crores reported in the previous quarter, as well as a nearly 15 percent rise compared to Rs. 4.08 crores in Q4 FY24. EBITDA margins stood at 12.29 percent in Q4 FY25, down from 13.34 percent recorded in Q3 FY25, but up from 10.29 percent posted in Q4 FY24. The company’s Board recommended a dividend of Rs. 1.5 per equity share of face value of Rs. 10 each (15 percent) for FY25.
About the company
Smruthi Organics Limited is a manufacturer of Active Pharmaceutical Ingredient (API) products in the Anti-Diabetic, Anti-Hypertension and Anti-Infectives Therapeutic categories, catering to both the Indian domestic as well as the rest of the world (ROW) markets, with clients spanning across Asia, Americas, and Africa.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
